CD8A and neoplasm: CD73/adenosine axis inhibitor: AB680 (anti-CD73 humanized monoclonal antibody, IC50=0.8 nM) reduced tumor adenosine concentration by 72% in gastric cancer PDX models, increased CD8+ T cell infiltration by 3.1-fold, and achieved a tumor suppression rate of 58% in CD73/Adora2b co-expression models (p<0.01) (30).